Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

August 17, 2023

Study Completion Date

December 31, 2024

Conditions
High Grade GliomaAstrocytoma, Grade IIIGlioblastoma
Interventions
DRUG

BMX-001

BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.

RADIATION

Radiation Therapy

RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy.

DRUG

Temozolomide

Initially, temozolomide (TMZ) will be dosed at 75 mg/m2 orally daily for 42 days. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles.

Trial Locations (9)

27710

Duke Cancer Institute, Durham

35294

University of Alabama- Birmingham, Birmingham

40536

University of Kentucky, Lexington

43210

Ohio State University, Columbus

64111

St. Luke's Hospital, Kansas City

68198

University of Nebraska Medical Center, Omaha

84112

Huntsman Cancer Institute, Salt Lake City

94143

University of California San Francisco, San Francisco

98195

University of Washington, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Duke Cancer Institute

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

BioMimetix JV, LLC

INDUSTRY

NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 | Biotech Hunter | Biotech Hunter